Therapy of inflammatory rheumatic diseases: From standard into the future;Therapie entzündlich-rheumatischer erkrankungen: Vom standard in die zukunft

Internist

Volumn 42, Issue 2, 2001, Pages 223-236

  Gause, A ^a   Manger, B ^b   Kalden, J R ^b   Burmester, G R ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FUTUROLOGY; HUMAN; INFLAMMATORY DISEASE; REVIEW; RHEUMATIC DISEASE; STANDARD;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTIRHEUMATIC AGENTS; ARTHRITIS; GERMANY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; VASCULITIS;

EID: 0035100650     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050746     Document Type: Review

References (89)

1. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)
2. Rheumatoid arthritis: Pathophysiology and implications for therapy
3. Kombination langwirksamer antirheumatika (sog. basis-therapeutika) bei der theumatoiden arthritis
4. In vivo blockade of TNF-alpha by i.v. infusion of a chimeric, monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: Short term cellular and molecular effects
5. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
6. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
7. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
8. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
9. Consensus statement: Access to disease modifying treatments for rheumatoid arthritis patients
10. Consensus statement on the initiation and continuation of TNF blocking therapies in rheumatoid arthritis
11. A multicenter, double-blind, dose-ranging, randomized, placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
12. rHUMIL10 in subjects with active rheumatoid arthritis: A phase I and cytokine response study
13. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma
14. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40
15. Managing seronegative spondarthritides
16. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone
17. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
18. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
19. Efficacy of methotrexate in the treatment of ankylosing spondylitis: A three-year open study
20. Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): An open trial
21. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
22. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: Clinical outcome and followup by dynamic magnetic resonance imaging
23. Induction of malignant bone tumors in radium-224 patients: Risk estimates based on the improved dosimetry
24. Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis
25. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
26. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
27. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab
28. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study
29. Managing reactive arthritis
30. Treatment of reactive arthritis with antibiotics
31. Reactive arthritis
32. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
33. The spondyloarthropathies
34. Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis
35. Successful treatment of severe Reiter's syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases
36. Enteropathische spondarthritiden
37. Interventions for psoriatic arthritis
38. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis
39. Renal toxicity of long-term cyclosporin
40. Treatment of psoriatic arthritis: Open prospective study comparing efficacy and safety profile between leflunomides vs methotrexate
41. Successful treatment of severe psoriatic arthritis with infliximab
42. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
43. Prophylaxe und therapie der Lyme-Borreliose
44. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
45. How to improve morbidity and mortality in systemic lupus erythematosus
46. Konventionelle immunsuppression chronisch-entzündlicher systemerkrankungen
47. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis
48. The use of methotrexate in steroid-resistant lupus erythematosus
49. Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study
50. Mycophenolat mofetil for systemic lupus erythematosus
51. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
52. Treatment of lupus nephritis - A work in progress
53. Treatment of severe systemic lupus erythematosus with high-dos chemotherapy and haemopoietic stem-cell transplantation: A phase I study
54. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus
55. Interaction between CD40 and its ligand gp39 in the development of lupus nephritis
56. Treatment of murine lupus with CTLA4Ig
57. New therapies for systemic lupus erythematosus
58. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study
59. Corticosteroids: Do they damage the cardiovascular system?
60. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?
61. Systemic lupus erythematosus: Clinical features in patients with a disease duration of over 10 years, first evaluation
62. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients
63. Nomenclature of systemic vasculitides. Proposal of an international consensus conference
64. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
65. Development and validation of a disease extent index for ANCA-associated vasculitides
66. Primär systemische vaskulitiden. Teil III: Pathogenese und therapie
67. ANCA-assoziierte vaskulitiden, neue konzepte und strategien in der therapie
68. New directions in allergic diseases: Mechanism-based anti-inflammatory therapies
69. Are chemokines essential or secondary participants in allergic responses?
70. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
71. Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: Experience in four cases
72. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
73. Cytokine profiles in Wegener's granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation
74. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis
75. Maintenance of remission with leflunomide in Wegeners granulomatosis
76. Mycephenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
77. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha
78. Hepatitis C virus-associated cryoglobulinemic vasculitis. Physiopathology, diagnosis and therapy
79. Regulation of B cell function by the immunosuppressive agent leflunomide
80. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis
81. Modulating the Th1/Th2 balance in inflammatory arthritis
82. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
83. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases
84. Immunotherapy for autoimmune and inflammatory renal diseases
85. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits
86. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion
87. Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation
88. Consensus therapeutic regimens for ANCA-associated systemic vasculitis